Evidence map›Paper›PMID 32642851›Full record

ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2020

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?

S Rozenberg, N Al-Daghri, M Aubertin-Leheudre, M-L Brandi, A Cano, P Collins, C Cooper, A R Genazzani, T Hillard, J A Kanis and 11 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 8 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 8 syntheses or guidelines pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Effectiveness ofFrontiers in endocrinology · 2022
    Pooled it
  9. Trial
  10. Trial
  11. Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women's Health Initiative hormone therapy trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Trial
  12. Review
  13. Dietary and supplemental calcium intake and bone changes during antiresorptive osteoporosis treatment in older women: a longitudinal observational study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  14. Revised Swedish FRAX models and the establishment of age-dependent intervention thresholds.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 20 institutions in 12 countries.

S RozenbergDepartment of Obstetrics and Gynecology CHU St Pierre, Université Libre de Bruxelles, Vrije Universiteit, Brussels, Belgium.
N Al-DaghriChair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.
M Aubertin-LeheudreDepartment of Physical Activity Sciences, Faculty of Sciences, Université du Québec à Montréal, CRIUGM, Montreal, Québec, Canada.
M-L BrandiDepartment of Biochemical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
A CanoDepartment of Obstetrics and Gynecology, University of Valencia and INCLIVA Health Research Institute, Valencia, Spain.
P CollinsNational Heart and Lung Institute, Imperial College London, London, UK.
C CooperMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
A R GenazzaniDivision of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
T HillardDepartment of Obstetrics & Gynaecology, Poole Hospital NHS Trust, Poole, UK.
J A KanisMary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
J-M KaufmanDepartment of Endocrinology, Ghent University Hospital, Ghent, Belgium.
I LambrinoudakiMenopause Unit, 2nd Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
A LaslopScientific Office, Federal Office for Safety in Health Care, Vienna, Austria.
E McCloskeyCentre for Integrated research in Musculoskeletal Ageing, Mellanby Centre for Bone Research, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
S PalaciosDirector of Palacios Institute of Women's Health, Madrid, Spain.
D Prieto-AlhambraCentre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
J-Y ReginsterWHO Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liege, Belgium.
R RizzoliDivision of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
G RosanoIRCCS San Raffaele, Rome, Italy.
F TrémollieresMenopause Center, Hôpital Paule de Viguier, University Hospital of Toulouse and INSERM U1048-I2MC-Equipe 9, Toulouse, France.
N C HarveyMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK. nch@mrc.soton.ac.uk.ORCID http://orcid.org/0000-0002-8194-2512
University Hospital Southampton NHS Foundation Trust · GBAustralian Catholic University · AUAustrian Agency for Health and Food Safety · ATAzienda Ospedaliero-Universitaria Careggi · ITGhent University Hospital · BEInserm · FRInstituto Palacios · ESIRCCS Ospedale San Raffaele · ITKing Saud University · SANational and Kapodistrian University of Athens · GRNuffield Orthopaedic Centre · GBPoole Hospital · GBRoyal Brompton Hospital · GBUniversitat de València · ESUniversité du Québec à Montréal · CAUniversité Libre de Bruxelles · BEUniversity Hospital of Geneva · CHUniversity of Liège · BEUniversity of Pisa · ITUniversity of Sheffield · GB

Funding

Medical Research Council MC_UU_12011/1Versus Arthritis 17702Versus Arthritis 21231
6 · The paper itself

Abstract

We provide an evidence base and guidance for the use of menopausal hormone therapy (MHT) for the maintenance of skeletal health and prevention of future fractures in recently menopausal women. Despite controversy over associated side effects, which has limited its use in recent decades, the potential role for MHT soon after menopause in the management of postmenopausal osteoporosis is increasingly recognized. We present a narrative review of the benefits versus risks of using MHT in the management of postmenopausal osteoporosis. Current literature suggests robust anti-fracture efficacy of MHT in patients unselected for low BMD, regardless of concomitant use with progestogens, but with limited evidence of persisting skeletal benefits following cessation of therapy. Side effects include cardiovascular events, thromboembolic disease, stroke and breast cancer, but the benefit-risk profile differs according to the use of opposed versus unopposed oestrogens, type of oestrogen/progestogen, dose and route of delivery and, for cardiovascular events, timing of MHT use. Overall, the benefit-risk profile supports MHT treatment in women who have recently (< 10 years) become menopausal, who have menopausal symptoms and who are less than 60 years old, with a low baseline risk for adverse events. MHT should be considered as an option for the maintenance of skeletal health in women, specifically as an additional benefit in the context of treatment of menopausal symptoms, when commenced at the menopause, or shortly thereafter, in the context of a personalized benefit-risk evaluation.

Indexed as

Estrogen Replacement TherapyOsteoporosis, PostmenopausalEstrogensFemaleHormone Replacement TherapyHumansMenopauseMiddle AgedEstrogensCardiovascularEpidemiologyHormone therapyMenopauseOsteoporosisSafety

Identifiers

PMID32642851
PMCPMC7661391
OpenAlexW3041032524

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.